Morepen Laboratories Overview
- Founded
-
1984
- Status
-
Public
- Employees
-
1,510
- Stock Symbol
-
500288
- Share Price
-
$0.44
- (As of Monday Closing)
Morepen Laboratories General Information
Description
Morepen Laboratories Ltd is an India based pharmaceutical company. It develops, manufactures and markets generic drugs and pharmaceutical formulations. The company's products include Tablets, Capsules, Injections, Ointments, Syrups, and Powders. It also offers products under brands Burnol, Lemolate and Fiber-X. The company's geographical markets include India, the United States and the rest of the world, with a majority of revenue being generated in India.
Contact Information
Primary Industry
Pharmaceuticals
Stock Exchange
BOM
Primary Office
- 409, Antriksh Bhawan
- 22 Kasturba Gandhi Marg
- New Delhi, Delhi 110001
- India
+91 098183 00000
Morepen Laboratories Stock Performance
(As of Monday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.44 | $0.45 | $0.41 - $0.84 | $221M | 499M | 232K | $0.02 |
Morepen Laboratories Financials Summary
|
In Thousands, USD |
TTM 30-Jun-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 240,501 | 225,195 | 189,805 | 54,994 |
| Revenue | 194,084 | 207,607 | 159,685 | 118,170 |
| EBITDA | 15,528 | 19,727 | 17,551 | 10,318 |
| Net Income | 10,197 | 13,647 | 13,049 | 4,726 |
| Total Assets | 141,115 | 116,841 | 87,969 | |
| Total Debt | 0 | 2,449 | 2,321 | 1,786 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Morepen Laboratories Patents
Morepen Laboratories Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-10626093-B2 | Polymorphic form of crystalline rosuvastatin calcium and novel processes for crystalline as well as amorphous rosuvastatin calcium | Active | 18-Apr-2016 | 0000000000 | 0 |
| US-20190127334-A1 | New polymorphic form of crystalline rosuvastatin calcium & novel processes for crystalline as well as amorphous rosuvastatin calcium | Granted | 18-Apr-2016 | 0000000000 | |
| EP-3445751-A4 | New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium | Pending | 18-Apr-2016 | 0000000000 | |
| EP-3445751-A1 | New polymorphic form of crystalline rosuvastatin calcium&novel processes for crystalline as well as amorphous rosuvastatin calcium | Pending | 18-Apr-2016 | 0000000000 | |
| AU-2003253247-A1 | An improved method for the preparation of montelukast acid and sodium salt thereof in amorphous form | Abandoned | 06-Jun-2003 | C07D215/18 |
Morepen Laboratories Executive Team (1)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Varun Suri | Chief Executive Officer |
Morepen Laboratories Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Morepen Laboratories Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|